AUC 0-24h , area under the plasma concentration-time curve from 0 to 24 h; AUC 0-t (Shimokawa et al., 2015) . The metabolic activities in dogs and humans are higher than those in rodents. In this study, we characterized the pharmacokinetics and metabolism of delamanid in animals and humans. Eight metabolites (M1 to M8) produced by cleavage of the imidazooxazole moiety of delamanid were identified in the plasma after repeated oral administration by liquid chromatography-mass spectrometry analysis. Delamanid was initially catalyzed to M1 and subsequently metabolized by 3 separate pathways, which suggested that M1 is a crucial starting point. The major pathway in humans was hydroxylation of the oxazole moiety of M1 to form M2 and then successive oxidation to the ketone form (M3) mainly by CYP3A4. M1 had the highest exposure among the 8 metabolites after repeated oral dosing in humans, which indicated that M1 was the major metabolite. The overall metabolism of delamanid was qualitatively similar across nonclinical species and humans, but quantitatively different among the species. After repeated administration, the metabolites had much higher concentrations in dogs and humans than in rodents. The in vitro metabolic activity of albumin on delamanid probably caused the species differences observed. We determined that albumin metabolism is a key component of the pharmacokinetics and metabolism of delamanid. Nonhepatic formation of M1 and multiple separate pathways for metabolism of M1 suggest that clinically significant drugdrug interactions with delamanid and M1 are limited.
DMD#064527

Introduction
Delamanid (OPC-67683, Deltyba TM , nitro-dihydro-imidazooxazole derivative), (R)-2-methyl-6-nitro-2- [(4-{4-[4-(trifluoromethoxy) phenoxy]piperidin-1-yl}phenoxy)methyl]-2,3-dihydroimidazo[2,1-b]oxazole, was developed by Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan) as a new anti-tuberculosis agent for the treatment of multidrug-resistant tuberculosis (MDR-TB) , and it reduces mortality in affected patients (Diacon et al., 2011; Gler et al., 2012; Skripconoka et al., 2013) . The action mechanism of delamanid is the inhibition of mycolic acid synthesis in the bacterium Mycobacterium tuberculosis .
Delamanid received regulatory approval in the European Union, Japan, and Korea in 2014 as part of combination therapy with a regimen of World Health Organization (WHO)-recommended second-line drugs.
An estimated 9 million people became sick with TB and 1.5 million people died from TB or TB-related causes in 2013 (WHO, 2014) . Current TB treatment is long and cumbersome and requires ≥ 6 months of multidrug chemotherapy that typically uses firstline drugs, such as rifampicin, isoniazid, ethambutol, and pyrazinamide. Furthermore, MDR-TB may result when TB therapy is discontinued, interrupted or when improper drug regimens, including monotherapy, are prescribed (Blumberg et al., 2003) . MDR-TB treatment may require >2 years of chemotherapy with less effective and more toxic second-line drugs (Horsburgh et al., 2000; Shin et al., 2004) . Furthermore, there are many patients with TB-HIV/AIDS co-infection, and an estimated 1.1 million new TB cases were reported among people with HIV/AIDS (WHO, 2014) . TB is still a leading cause of morbidity and mortality among patients with HIV/AIDS (Joint United Nations This article has not been copyedited and formatted. The final version may differ from this version. Programme on HIV/AIDS, 2013). Therefore, new drugs, such as delamanid, have been sought to improve the therapeutic value of TB chemotherapy.
As described above, concomitant treatment is the cornerstone of TB treatment, and delamanid will be administered with various drugs, including medicines for TB and HIV/AIDS. Ritonavir, nelfinavir, saquinavir, and amprenavir, which are HIV protease inhibitors, inhibit cytochrome P450 (CYP) activity (Granfors et al., 2006) . Conversely, rifampicin induces CYP2B6 and CYP3A4 (Dooley et al., 2012) . Alterations caused by efavirenz, an anti-retroviral drug known to be a CYP3A4 inducer, in the pharmacokinetics of co-administered drugs, lead to the lack of efficiency or adverse drug reactions of the victim drug (Deeks and Perry, 2010) . Therefore, when administered concomitantly, these drugs may either increase or decrease the plasma concentrations of other co-administered drugs and their metabolites.
Drug-metabolizing enzymes have a vital role in eliminating drugs from the body.
About 75% of drug-transformation reactions, i.e., metabolism, involve catalysis by CYP isozymes, which suggests that the CYP complex of enzymes is very important in drug metabolism (Flockhart, 2007; Guengerich and Rendic, 2010; Wienkers and Heath, 2005) .
In humans, CYP isozymes perform highly specific reactions, such as oxidation of DMD#064527 7 reported that plasma albumin was involved in the metabolism of delamanid. Delamanid was rapidly degraded to M1, a unique metabolite formed by cleavage of the 6-nitro-2,3-dihydroimidazo [2,1-b] oxazole moiety, by incubation in human plasma at 37°C, with a half-life of 0.64 h. Furthermore, these metabolic activities of albumin were much higher in dogs and humans than in rodents, a finding that suggests species differences. However, pharmacokinetic and metabolic profiles for delamanid including evaluation of albumin contribution, have not been clarified.
It is important to understand the pharmacokinetic and metabolic profiles for new drugs in animals and humans so that the impact on efficacy and safety can be interpreted or predicted. In this study, we investigated the metabolic pathways, interspecies pharmacokinetics, and CYP enzymes that catabolize delamanid and characterized the pharmacokinetics and metabolism of delamanid in animals and humans. DMD#064527 9 rats at 5 weeks of age were supplied from Charles River Laboratories Japan, Inc. Male and female beagle dogs at 6 months old were supplied from Covance Research Products, Inc. (Cumberland, VA). Environmental conditions were set to maintain an air-exchange rate of 13-17 times/h and maintained at 18°C to 26°C with 30% to 80% relative humidity in the housing room that was lighted for 12 h (7:00-19:00) daily. Animals were individually housed and allowed free access to tap water via an automatic water supply system. Male mice and rats were provided with pelleted food (CRF-1, sterilized by radiation; Oriental Yeast Co., Ltd., Tokyo, Japan) ad libitum. Male and female dogs were supplied with 300 g/day of pellet diet (DS-A; Oriental Yeast Co., Ltd. or CD-5M; Clea Japan, Inc., Tokyo, Japan).
The animal experimental protocols and procedures were reviewed in accordance with Guidelines for Animal Care and Use in Otsuka Pharmaceutical Co., Ltd. and approved by the in-house Animal Ethics Committee. The human trial protocol, available with the full text of another report (Gler et al., 2012) , was approved by independent ethics committees and institutional review boards for all sites. All male and female patients provided written informed consent in their native language before enrollment. The trial was performed in accordance with the Good Clinical Practice guidelines of the International Conference on Harmonization (ICH-GCP), adhered to the ethical principles of the Declaration of Helsinki, and was monitored by an independent data and safety monitoring committee.
Investigation of Metabolites
After repeated dosing at 100 mg/kg/day for 14 days to 6 male mice and 3 male rats, blood was withdrawn into heparinized syringes at 8 h and 24 h. Blood from male This article has not been copyedited and formatted. The final version may differ from this version. and female dogs (n = 3, each sex) was withdrawn into heparinized syringes at 24 h after the final oral dosing at 100 mg/kg/day for 13 weeks. After centrifugation at approximately 1700 × g for 10 min at 4°C, the supernatants were stored at −15°C or below until use. Plasma samples for each sex and at each sampling point were equally mixed. After the plasma sample was mixed with an equal volume of acetonitrile, the mixture was centrifuged at 12000 × g for 5 min at 4°C. A 5-μL aliquot of the supernatant was analyzed by liquid chromatography with tandem mass spectrometry (LC-MS/MS). In addition, another 0.6-mL aliquot of the plasma sample was extracted with 5 mL of ethyl acetate by shaking for 10 min. After centrifugation as above, the organic layer was evaporated to dryness at 40°C. The residue was dissolved in 0.1 mL of acetonitrile/water Corp., Yamaguchi, Japan) with a binary gradient solvent system consisting of A: water/acetic acid (100:1, v/v) and B: acetonitrile/ acetic acid (100:1, v/v); the chromatography was performed using a Nanospace SI-2 HPLC system (Shiseido Co., Ltd., Tokyo, Japan). The column temperature was maintained at 40°C, and the flow rate was 0.2 mL/min. LC eluate was introduced directly into an API3000 triple-quadrupole mass spectrometer (AB SCIEX, Foster, CA), equipped with an electrospray ionization interface operated in positive-ion mode with the following operation parameters: gas temperature, 475°C; gas flow rate, 7 L/min; gas pressure, 70 psi; ion-spray voltage, 4.5 kV; nebulizer gas, 12 units; curtain gas, 8 units; and collision gas, 8 units. 
Exposure to Delamanid and its Metabolites
Animal blood samples in the single-dose pharmacokinetic study were collected as follows: 1, 2, 4, 6, 8, 12, 24, 32, 48, 72, 96, 144, 192, 288 , and 480 h after the single dosing at 3 mg/kg in mice and rats (n = 3) and 2, 4, 6, 8, 12, 24, 32, 48, 72, 96, 144, 192, 240, 288, 384, 480, 576 , and 768 h after the single dosing at 10 mg/kg in dogs (n = 4). In the repeated dose study, the animal blood was collected at 2, 4, 6, 8, and 24 h on day 1 (mice and rats, n = 3), at 13 weeks (mice, n = 3), and 26 weeks (rats, n = 3), and 2 and 6 h on day 1 (dogs, n = 4), and 1, 2, 6, 8, and 24 h at 39 weeks (dogs, n = 4) after oral dosing at 30 mg/kg/day. The human blood was withdrawn at 0, 2, 3, 4, 10, 12, 13, 14, and 24 h after oral dosing on days 1, 14, 28, and 56 after oral dosing at 100 mg bis in die (BID; twice a day) in human (n = 144).
The blood samples were immediately placed in an ice bath and centrifuged at 1800 g for >10 min at 4°C to obtain plasma. The plasma samples were stored at −15°C or below until assay. The plasma concentrations of delamanid and its metabolites were simultaneously determined by LC-MS/MS and validated according to Food and Drug Administration guidance, including selectivity, accuracy, precision, recovery, calibration curve, post-preparative stability, freeze-thaw stability, short-term stability, and long-term stability. The sample analyses were performed under the optimal conditions of stability. spray voltage, 4.5 kV; electron-multiplier voltage, 1.45 kV; nitrogen sheath gas pressure, 80 psi; nitrogen auxiliary gas pressure, 10 (arbitrary units); argon collision gas pressure, 2.0 mTorr; capillary temperature, 260°C. Data acquisition and processing were performed using Xcalibur software version 1.2 (Thermo Fisher Scientific Inc.). The calibration curve ranges of delamanid for mouse, rat, and dog plasma were 6-2000 ng/mL, 3-1000 ng/mL, and 3-1000 ng/mL, respectively, and those of the metabolites were 6-600 ng/mL, 3-300 ng/mL, and 3-1000 ng/mL, respectively. In humans, the concentrations of This article has not been copyedited and formatted. The final version may differ from this version. 
Identification of Human CYP Isoforms
For recombinant studies, the following recombinant microsomes were used in duplicate: CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Each incubation contained recombinant microsomes (0.7 mg/mL, 50 nM of CYP protein), phosphate buffer (100 mM, pH 7.4), metabolites (10 μ M M1 or M2), NADPH (2.5 mM), and NADH (2.5 mM) in a total volume of 0.5 mL. Incubation mixtures were pre-incubated at 37°C for 5 min, and reactions were started by adding a mixture of NADPH and NADH. After 0, 10, and 30 min of incubation at 37°C, the reactions were terminated with 1 mL of acetonitrile, containing the internal standard (IS; in-house compound). After centrifugation, the supernatant was analyzed by LC-MS/MS. For furafylline and ticlopidine, the prereaction was performed without delamanid derivative for 15 min. Reactions were performed at 37°C for a set time period within the time linearity limit (M2 from M1 for 40 min and M3 from M2 for 180 min). After the addition of 1 mL of acetonitrile containing IS, the solution was centrifuged, and the supernatant was analyzed by LC-MS/MS, referring to the animal methods.
Binding of Metabolites to the Serum
The in vitro binding of M1, M4, and M5 at the concentrations of 500 and 5000 ng/mL to animal and human sera was determined by equilibrium dialysis using a Spectra/Por2 molecular porous dialysis membrane (Spectrum Laboratories, Inc., Rancho Dominguez, CA). Because M1, M4 and M5, unlike delamanid, are stable in the serum at 37°C, equilibrium dialysis was conducted under the condition for 8 h at 37°C. After dialysis for protein binding, an aliquot of the dialyzed protein and dialysate in the 2 devices was sampled to determine the concentrations in the bound and unbound fractions.
Cooled tert-butyl ether (mouse and rat) or diethyl ether (dog and human) containing IS was added to the sample and shaken for >5 min. The organic layer was evaporated, and the residue was dissolved in water/methanol/formic acid (50:50:1, v/v/v). The supernatant was analyzed using the modified LC-MS/MS method as described above.
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Investigation of Metabolites in Plasma
Initially we performed full-scan LC-MS analysis using the plasma extracts from mice, rats, and dogs following repeated oral doses of delamanid, but no peaks were Fig. 2) . Therefore, a precursor-ion scan at m/z 352 was performed, and 8 metabolites, M1 to M8, were detected in male dog plasma (Fig. 1A) , as well as female one. Sex difference was not observed. The intensities of these peaks monitored at UV 254 nm were much lower than the intensity of delamanid, and no other remarkable peak was observed in the dogs (Fig. 1B) . In addition, the mouse and rat plasma also showed no remarkable metabolites other than M1 to M8 (data not shown). The chemical structures of these metabolites were determined by matching retention times, parent m/z ions, and MS/MS fragmentation patterns with those of the authentic compounds (Table 1, Supplemental Fig. 2 ). Fig. 2 and Table 2 present information characterizing the pharmacokinetic behavior of an oral dose of delamanid in mice, rats, and dogs. After the administration of a single 3 mg/kg delamanid to mice, the maximum plasma concentration of delamanid (478.7 ng/mL) occurred at 2 h, followed by a decline in the plasma level with elimination t 1/2,z of 7.2 h. In the rats, delamanid (3 mg/kg) absorption had a t max of 4 h and a C max of 600.5 ng/mL. The t 1/2,z (5.1 h) was similar to that obtained in the mice. In the dogs treated with oral delamanid (10 mg/kg), the t max and C max were 8 h and 357.8 ng/mL, respectively. This article has not been copyedited and formatted. The final version may differ from this version. The t 1/2,z in dogs was 18.4 h, which was longer than that in the rodents. In all animal species, the plasma concentrations of the delamanid metabolites were much less than the concentration of the parent compound. The metabolites appeared slowly in plasma, and had very long MRT and elimination half-lives in the dogs (Figs. 2C-1 and C-2 Table 3 lists the mouse, rat, dog, and human C max and AUC values. The C max of delamanid in male mouse plasma reached 2920.9 ng/mL at 6 h after repeated administration of 30 mg/kg/day. The C max in the male rat plasma reached 1799.2 ng/mL at 4 h. The extent of delamanid absorption (C max and AUC) did not alter significantly on multiple administrations in the mice and rats. The C max of delamanid in male dog plasma reached 1400.7 ng/mL at 3 h after repeated administration at 30 mg/kg/day, and decreased with time. There was no remarkable difference between the ratios of delamanid between males and females in the rodents and dogs (data not shown). The C max of delamanid in the human plasma reached 135 and 414 ng/mL after single and repeated administration at 100 mg BID, respectively. Approximately 3.7-and 3.1-fold delamanid accumulation was observed after repeated administration in dogs and humans, respectively (Table 3, Fig. 3 ). There was no difference among the C max and AUC values for delamanid on days 14 to 56 in humans; therefore, a steady-state delamanid concentration was reached at ≤ 14 days (Fig. 3) . 
Single-dose Pharmacokinetics of Delamanid and Metabolites
Multiple-dose Pharmacokinetics of Delamanid and Metabolites
Identification of Human CYP Isoforms
The major circulating metabolites of delamanid in humans were M1 and M3. The metabolite M1 has been shown to be produced from delamanid by albumin in plasma (Shimokawa et al., 2015) via extrahepatic metabolism. We further examined the types of CYP enzymes involved in the formation of M3 from M1 via M2 in humans using recombinant CYP enzymes and human liver microsomes with CYP inhibitors.
Among the 11 recombinant human CYP enzymes studied (CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5), CYP1A1, CYP3A4, CYP2D6, and CYP2E1 time-dependently catalyzed the hydroxylation of M1 to M2 (Fig. 4A) . No production of M2 was detected in the other CYP expression microsomes. Furthermore, CYP1A1 and CYP3A4 showed timedependent metabolism of M2 to M3, and in the other CYPs, no production of M3 was detected (Fig. 4B) . The metabolic activity of hydroxylation and dehydrogenation in recombinant human CYP1A1 was the highest among the 11 recombinant human CYP enzymes examined.
In the assay containing specific inhibitors for CYP (furafylline, ticlopidine, sulfaphenazole, benzylnirvanol, quinidine, and ketoconazole), only ketoconazole whereas other inhibitors were ineffective (Fig. 5) . These results indicated that CYP3A4 was mainly responsible for M2 and M3 formations in humans.
Binding of Metabolites to Serum
The in vitro protein binding of M1, M4, and M5 in mouse, rat, dog, and human sera is shown in Table 4 . Calculation of protein binding for almost all metabolites at concentrations of 500 ng/mL was not performed because the metabolite levels in the buffer side were extremely low, which indicated high protein binding. At 5000 ng/mL, M1, M4, and M5 showed high protein binding (98.7%-99.8%). No differences in the metabolite intersubstrate and interspecies in addition to delamanid were observed.
DMD#064527
Discussion
Eight compounds were detected as circulating metabolites after repeated oral administration of delamanid in mice, rats, and dogs (Fig. 1) . Drug-related peaks, except those for delamanid and its 8 metabolites, were not observed on UV chromatograms (Fig.   1B) , which indicated that there were no other significant metabolites in the plasma. All metabolites had a common product ion at m/z 352 (Table 1) , which is produced by the loss of the nitro-dihydro-imidazooxazole moiety of delamanid (Supplemental Fig. 2) .
Delamanid, M1, M2, M4, M5, M6, M7, and M8 gave the characteristic and intense product ions at m/z 357, 288, 302, 289, 306, 305, 305, and 303, respectively (Table 1) , which were generated by the loss of the trifluoromethoxy phenol moiety (Supplemental Fig. 2) . These results suggest that the nitro-dihydro-imidazooxazole moiety is the main metabolic target site of delamanid. An analog of delamanid, PA-824, which currently is being developed in a clinical trial for TB therapy, has a 2-nitro-imidazooxazine as well.
PA-824 is metabolized mainly at the nitro-imidazole moiety in the liver (Dogra et al., 2011) ; hence, delamanid and PA-824 have a common metabolic target site, which suggests that this moiety has a position with high metabolic reactivity.
After consideration of our findings, we propose metabolic pathways of delamanid. In general, metabolic reactions, such as a monooxygenase reaction and hydrogen abstraction reaction, are simple. In contrast, metabolic reactions of delamanid and M1 are complicated. Our most recent evidence indicates that delamanid is rapidly degraded to M1 by incubation in human plasma at 37°C with a half-life of 0.64 h via a plasma albumin-mediated reaction (Shimokawa et al., 2015) . NADPH-dependent metabolites have been hardly detected in human liver microsomes . Therefore, albumin is considered to mainly produce M1 from delamanid. Moreover, all metabolites (M1 to M8) were detected in the animals following M1 administration (data not shown), which suggested that M1 is a crucial starting point of the metabolic pathway.
In this study, following oral administration of delamanid to animals and humans, M1 to M8 were detected and identified in plasma. After considering these findings, delamanid is thought to be primarily formed by hydrolytic cleavage of the hydroimidazo-oxazole moiety to (R)-2 amino-4,5-dihydrooxazole derivative (M1) and further catalyzed by 3 pathways (Fig. 6A) . The first metabolic pathway (pathway 1) is hydroxylation of the oxazole moiety (M2) followed by oxidation of hydroxyl group and tautomerization of oxazole to a imino-ketone metabolite (M3, Fig. 6B-1) . The second metabolic pathway (pathway 2) is hydrolysis and deamination of the oxazole amine (M4, Fig. 6B-2) followed by hydroxylation to M6 and M7 and oxidation of oxazole to another ketone metabolite (M8). The third metabolic pathway (pathway 3) is hydrolytic cleavage of the oxazole ring (M5, Fig. 6B-3 ).
After repeated administration of delamanid, the highest exposure in human subjects was to the parent compound (40% of the total exposure) followed by the metabolites M1 (18%) and M3 (13%) ( Table 3) . M1 showed the highest exposure among the 8 metabolites after repeated oral dosing in humans, which indicated that M1 is the predominant metabolite. The proposed major metabolic pathway of delamanid in humans is considered to be pathway 1. The exposures of M3 (17%), M1 (17%), M8 (13%), and M2 (12%) were high in the male dog plasma after repeated administration, which suggested that pathway 1 is the most important in dogs, followed by pathway 2.
Conversely, exposure to M7 (4%-10%) was high in mice and rats, which suggested that This article has not been copyedited and formatted. The final version may differ from this version. pathway 2 is the most important in rodents. We consider that the metabolic pathways in dogs were similar to those in humans but dissimilar to those in rodents.
Qualitatively, the 8 metabolites were commonly observed in the animals and humans evaluated. However, there was a quantitative difference among the species (Table   3 ). The exposure ratios of the AUCs of all metabolites (M1-M8) to the total AUC 0-24h were much higher in dogs (71%) and humans (60%) than in rodents (15%-18%), which indicated that dog metabolism is quantitatively similar to that of humans (Table 3) .
Regarding the species differences, a larger amount of M1, which is a crucial starting point in the metabolic pathway, was generated in dogs and humans than in rodents (Table   3 ). An interesting finding was that the formation rates of M1 in dogs and humans were much higher than those in rodents in vitro via the plasma albumin-mediated reaction (Shimokawa et al., 2015) . This difference in M1 formation is likely to have a significant impact on the subsequent metabolism of delamanid.
Protein binding is an important factor regarding interspecies comparison of systemic exposure. Therefore, we determined plasma protein bindings of M1, M4, and M5 which are leading metabolites in each pathway. We found that there were no differences in the protein bindings of delamanid (Shimokawa et al., 2015) and these metabolites among mice, rats, dogs, and humans (Table 4) In humans, systemic exposure to delamanid after multiple oral dosing was 3.1 times higher than that after single administration, and a steady-state exposure was reached at 14 days (Fig. 3) . In dogs like human, plasma levels of delamanid and also the metabolites increased during multiple dosing. In particular, the increases in M1, M2, M3, and M8 were extraordinarily large ( Table 3 ). The accumulation is because of the extended half-lives (t 1/2,z : 108.0-884.2 h) of M1, M2, M3, and M8 (Fig. 2, Table 2 ). A possible explanation is that M1 distributes rapidly and becomes highly bound to many tissues.
Because of the high affinity, moving back to the plasma compartment would be slow.
This rapid tissue distribution and slow return to the plasma compartment may result in the extended half-lives in plasma. In fact, radioactive concentration in almost all tissues was higher than that in plasma following the administration of radiolabeled delamanid to rats (Miyamoto et al., 2005) . Representative organs such as lung (target organ), liver and kidney showed high M1 ratio to total radioactivity, whereas M1 was seen at a very low level in the plasma. Therefore, many tissues exhibited an extremely high distribution of M1 compared with the plasma. Moreover, M1 is likely oxidized after liver uptake, and the oxidized metabolites are returned more slowly to the plasma compartment.
We also carefully examined the activities of CYP isoforms involved in pathway 1, the major metabolic pathway in humans. The in vitro metabolism of M1 and its oxide (M2) was investigated using human recombinant CYP isoforms. Recombinant CYP1A1 and CYP3A4 converted these compounds to the oxidized metabolite, but other recombinant CYPs had little metabolic activity (Fig. 4) . Furthermore, we investigated the (Fig. 5) . On the basis of these studies, CYP3A4 is considered to be the major CYP isoform responsible for M2 and M3 formations. In addition, CYP3A4 was responsible for the reactions that formed M7 from M4 and M8 from M6 in the liver (data not shown), which involve similar hydroxylation and oxidation of the oxazole moiety. Conversely, CYP1A1 is not presumed to be principally involved in the metabolism because of the extremely low amounts of CYP1A1 in the human liver (Schweikl et al., 1993; Imaoka et al., 1996) . Therefore, CYP3A4 was thought to play an important role in the overall metabolism from M1. Nevertheless, we consider that delamanid and the key metabolite, M1, are less affected by inhibitor CYPs, probably because the metabolism of delamanid to M1 is due to the high contribution of albumin, a nonhepatic process, and M1 has multiple metabolic pathways. No significant changes in delamanid and M1 exposure occurred when delamanid was co-administered with lopinavir/ritonavir, a CYP3A4 inhibitor . Furthermore, delamanid is not affected by efavirenz, a CYP3A4 inducer . On the other hand, PA-824 exposures are substantially reduced by concomitant efavirenz while lopinavir/ritonavir had minimal effect on PA-824 exposures (Dooley et al., 2014) . These findings suggest that even though albumin metabolism may occur with PA-824, the contribution of albumin on PA-824 metabolism is lower than that for delamanid. These In conclusion, delamanid is primarily degraded to M1 by albumin in plasma and further catalyzed by 3 metabolic pathways, which indicates that M1 is a crucial starting point. M1 had the highest exposure among the 8 metabolites detected after repeated oral dosing in humans. M1 was subsequently oxidized to M3 via M2 mainly by CYP3A4. The pharmacokinetics and overall metabolism of delamanid show species differences, which are probably caused by the metabolic activity of albumin on delamanid. We concluded that M1 formation caused by albumin is the most important contributor to the pharmacokinetics and metabolism of delamanid. Clinically significant drug-drug interactions of delamanid and M1 with other drugs are considered to be limited. Plasma was collected at 24 h after daily oral dosing of delamanid at 100 mg/kg/day for 13 weeks. Shimokawa et al. (2015) . NC: not calculated (the concentration of the buffer side was below 6 ng/mL) Values are the mean of n = 3.
